Our research is based on the core principle that molecular interactions which occur in cancer cells can be targeted to block cancer growth.
Peer reviewed publications are the hallmark of sharing significant advancements in biomedical research.
ACT is leading innovation within the cancer biotechnology sector through its development and delivery of 'first in class' drugs.